PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22581300-0 2012 Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Docetaxel 100-109 Ras association domain family member 1 Homo sapiens 24-31 28350046-0 2017 [Corrigendum] Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Docetaxel 102-111 Ras association domain family member 1 Homo sapiens 38-45 22581300-3 2012 Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. Docetaxel 94-103 Ras association domain family member 1 Homo sapiens 41-48 22581300-7 2012 Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Docetaxel 163-172 Ras association domain family member 1 Homo sapiens 50-57 22581300-8 2012 Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer. Docetaxel 115-124 Ras association domain family member 1 Homo sapiens 41-48 23147544-0 2012 RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Docetaxel 166-175 Ras association domain family member 1 Homo sapiens 0-7 23147544-1 2012 BACKGROUND: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Docetaxel 176-185 Ras association domain family member 1 Homo sapiens 118-125